189 results on '"Ahn, Sylvie A."'
Search Results
2. La proteína de unión a los ácidos grasos cardíaca (HFABP) está relacionada con la gravedad de la insuficiencia cardíaca y sus biomarcadores cardíacos conocidos
- Author
-
Gruson Damien, Adamantidou Christina, Ahn Sylvie A., and Rousseau Michel F.
- Subjects
biomarcador ,insuficiencia cardíaca ,nt-probnp ,proteína de unión a los ácidos grasos cardíaca (hfabp) ,resultado ,riesgo ,Medical technology ,R855-855.5 - Abstract
Determinar las concentraciones de proteína de unión a los ácidos grasos cardíaca (HFABP) en pacientes con insuficiencia cardíaca con fracción de eyección reducida (ICFEr) y su potencial valor pronóstico.
- Published
- 2021
- Full Text
- View/download PDF
3. Heart-type fatty acid binding protein is related to severity and established cardiac biomarkers of heart failure
- Author
-
Gruson Damien, Adamantidou Christina, Ahn Sylvie A., and Rousseau Michel F.
- Subjects
biomarker ,heart failure with reduced ejection fraction (hfref) ,heart failure ,nt-probnp ,outcome ,risk ,Medical technology ,R855-855.5 - Abstract
To determine concentrations of heart-type fatty acid-binding protein (HFABP) in patients with heart failure with reduced ejection fraction (HFrEF) and its potential value for prognostic assessment.
- Published
- 2021
- Full Text
- View/download PDF
4. The antihyperlipidemic effect of a combined supplement of standardized dry extracts of amla (Emblica officinalis), walnut (Juglans regia), olive (Olea europaea) and red yeast rice (Monascus purpureus) powder: Reduction in circulatory low-density lipoprotein-cholesterol (LDL-C) and remnant cholesterol (RC) levels in patients with hypercholesterolemia
- Author
-
Hermans, Michel P., primary, Dierckxsens, Yvan, additional, Janssens, Isabelle, additional, Seidel, Laurence, additional, Albert, Adelin, additional, Ahn, Sylvie A., additional, Rousseau, Michel F., additional, and Khan, Amjad, additional
- Published
- 2023
- Full Text
- View/download PDF
5. Prognostic Value of Pulmonary Transit Time by Cardiac Magnetic Resonance on Mortality and Heart Failure Hospitalization in Patients With Advanced Heart Failure and Reduced Ejection Fraction
- Author
-
Houard, Laura, Amzulescu, Mihaela S., Colin, Geoffrey, Langet, Helene, Militaru, Sebastian, Rousseau, Michel F., Ahn, Sylvie A., Vanoverschelde, Jean-Louis J., Pouleur, Anne-Catherine, and Gerber, Bernhard L.
- Published
- 2021
- Full Text
- View/download PDF
6. Survival analysis of a large Belgian heart failure cohort with reduced ejection fraction
- Author
-
Menghoum, Nassiba, primary, Lejeune, Sibille, additional, Ahn, Sylvie, additional, Gerber, Bernhard, additional, Beauloye, Christophe, additional, and Pouleur, Anne-Catherine, additional
- Published
- 2022
- Full Text
- View/download PDF
7. Treatment with sodium-glucose cotransporter-2 inhibitors in heart failure patients: The potential benefits of monitoring FGF-23 levels?
- Author
-
UCL - SSS/IREC/EDIN - Pôle d'endocrinologie, diabète et nutrition, UCL - (SLuc) Service de biochimie médicale, UCL - (SLuc) Centre de pathologie sexuelle masculine, UCL - (SLuc) Service d'endocrinologie et de nutrition, UCL - SSS/IREC/CARD - Pôle de recherche cardiovasculaire, UCL - (SLuc) Service de cardiologie, Gruson, Damien, Pouleur, Anne-Catherine, Hermans, Michel, Ahn, Sylvie, Rousseau, Michel, UCL - SSS/IREC/EDIN - Pôle d'endocrinologie, diabète et nutrition, UCL - (SLuc) Service de biochimie médicale, UCL - (SLuc) Centre de pathologie sexuelle masculine, UCL - (SLuc) Service d'endocrinologie et de nutrition, UCL - SSS/IREC/CARD - Pôle de recherche cardiovasculaire, UCL - (SLuc) Service de cardiologie, Gruson, Damien, Pouleur, Anne-Catherine, Hermans, Michel, Ahn, Sylvie, and Rousseau, Michel
- Abstract
Inhibitors of sodium-glucose cotransporter 2 (SGLT2) inhibitors have shown effective glucose-lowering effects associated with improved clinical outcomes in diabetic patients and heart failure patients. As SGLT2 inhibitors can increase phosphate levels, they can also modulate FGF-23 production, a hormone directly involved in regulation of bone and mineral metabolism, but also a strong predictor of adverse cardiovascular events. We therefore discuss the relevance of FGF-23 as a companion testing of SGLT2 treatment, in addition to standard clinical biology tests.
- Published
- 2022
8. Performances of a novel chemiluninescence ABEI-based NT-proBNP immunoassay.
- Author
-
UCL - SSS/IREC/CARD - Pôle de recherche cardiovasculaire, UCL - SSS/IREC/EDIN - Pôle d'endocrinologie, diabète et nutrition, UCL - (SLuc) Service de pathologie cardiovasculaire, UCL - (SLuc) Service de biochimie médicale, Adamantidou, Christina, Ahn, Sylvie, Rousseau, Michel, Gruson, Damien, UCL - SSS/IREC/CARD - Pôle de recherche cardiovasculaire, UCL - SSS/IREC/EDIN - Pôle d'endocrinologie, diabète et nutrition, UCL - (SLuc) Service de pathologie cardiovasculaire, UCL - (SLuc) Service de biochimie médicale, Adamantidou, Christina, Ahn, Sylvie, Rousseau, Michel, and Gruson, Damien
- Abstract
Natriuretic peptides are widely used in clinical practice as cardiac markers for early diagnosis, prognosis and for the monitoring of treatment efficiency of heart Failure (HF). According to the clinical relevance of natriuretic peptides testing, it is important to assess the performances of novel platform for testing. Our study showed the overall good performances of a new NT-proBNP ABEI-based automated immunoassay.
- Published
- 2022
9. Fatty liver and atherogenic dyslipidemia have opposite effects on diabetic micro- and macrovascular disease.
- Author
-
UCL - SSS/IREC/EDIN - Pôle d'endocrinologie, diabète et nutrition, UCL - SSS/IREC/CARD - Pôle de recherche cardiovasculaire, UCL - (SLuc) Service d'endocrinologie et de nutrition, UCL - (SLuc) Service de cardiologie, Hermans, Michel, Bouenizabila, Evariste, Daniel Amoussou-Guenou, K, Jules Gninkoun, C, Ahn, Sylvie, Rousseau, Michel, UCL - SSS/IREC/EDIN - Pôle d'endocrinologie, diabète et nutrition, UCL - SSS/IREC/CARD - Pôle de recherche cardiovasculaire, UCL - (SLuc) Service d'endocrinologie et de nutrition, UCL - (SLuc) Service de cardiologie, Hermans, Michel, Bouenizabila, Evariste, Daniel Amoussou-Guenou, K, Jules Gninkoun, C, Ahn, Sylvie, and Rousseau, Michel
- Abstract
BACKGROUND AND AIMS: Non-alcoholic fatty liver (FL) is comorbid with obesity, metabolic syndrome and type 2 diabetes. Atherogenic dyslipidaemia (AD), frequent in FL, is associated with risk of micro- and macrovascular complications. Given the paradoxical ocular protection of FL in T2DM, we studied how FL modulates micro- and macrovascular complications as a function of AD. METHODS: Cross-sectional factorial analysis of 744 diabetic patients in whom FL, identified by ultrasonography, was present in 68%. AD, defined by low HDL-C plus elevated TG, was present in 45%. Four groups were analysed as regards cardiometabolic features, micro-/macroangiopathies, cataract and ocular hypertonia: FL[-]AD[-] (n = 171); FL[-]AD[+] (n = 66); FL[+]AD[-] (n = 235); and FL[+]AD[+] (n = 272). RESULTS: Age, gender and glycemic control were similar across groups. Prevalence of overall macroangiopathy and coronary artery disease were higher in patients with AD, irrespective of FL. Overall macroangiopathy was higher, by 64% in FL[-]AD[+] and by 38% in FL[+]AD[+]. Coronary artery disease was higher, by 128%, in FL[-]AD[+], and by 67%, in FL[+]AD[+]. (Micro)albuminuria was more frequent (+55%) in FL[-] AD[+] compared to FL[-] AD[-]. Retinopathy prevalence was 35% in FL[-], unaffected by AD. Retinopathy frequency was much lower in FL[+], irrespective of AD, decreased by -47% in FL[+]AD[-] and -32% in FL[+]AD[+] (vs. FL[-]AD[-]). Ocular hypertonia was present in 13%, and its prevalence was also markedly lower (-31%) in FL[+]. Cataract frequency was 29%, also lesser in FL[+] (24% vs. 39%), irrespective of AD. CONCLUSIONS: Multi-level eye protection in diabetes is linked to non-alcoholic fatty liver independently of atherogenic dyslipidemia.
- Published
- 2022
10. Pemafibraat en SPPARMα: een nieuwe klasse van vetverlagers
- Author
-
Hermans, Michel, Ahn, Sylvie, Rousseau, Michel, UCL - SSS/IREC/CARD - Pôle de recherche cardiovasculaire, UCL - (SLuc) Service de pathologie cardiovasculaire, UCL - SSS/IREC/EDIN - Pôle d'endocrinologie, diabète et nutrition, and UCL - (SLuc) Service d'endocrinologie et de nutrition
- Abstract
Pemafibraat is de eerste SPPARα die in de handel is gebracht voor de behandeling van dyslipidemie bij de mens. Het werkt selectief in op de nucleaire PPARα-receptoren en is ontwikkeld als alternatief voor de klassieke agonisten. Pemafibraat zorgt voor een hogere affiniteit voor de kernreceptoren, activeert de kernreceptoren sterker en veroorzaakt minder bijwerkingen. De PROMINENTstudie, een prospectieve, gerandomiseerde studie, onderzoekt momenteel het effect van pemafibraat op een atherogene dyslipidemie en de incidentie van cardiovasculaire accidenten bij type 2-diabetespatiënten.
- Published
- 2022
11. Pemafibrate et SPPARMa: une nouvelle classe d’agents hypolipémiants
- Author
-
Hermans, Michel, Ahn, Sylvie, Rousseau, Michel, UCL - SSS/IREC/EDIN - Pôle d'endocrinologie, diabète et nutrition, UCL - (SLuc) Service d'endocrinologie et de nutrition, UCL - (SLuc) Service de pathologie cardiovasculaire, and UCL - SSS/IREC/CARD - Pôle de recherche cardiovasculaire
- Abstract
Le pemafibrate est le premier agent pharmacologique SPPARα commercialisé pour le traitement de la dyslipidémie chez l’homme. Ce modulateur sélectif des récepteurs nucléaires PPARα a été développé comme alternative aux agonistes conventionnels, afin d’augmenter l’affinité et l’effet d’activation du récepteur nucléaire, tout en diminuant les effets secondaires potentiels. L’étude prospective randomisée en cours PROMINENT a pour but de déterminer si cette molécule, au-delà de ses effets bénéfiques sur la dyslipidémie athérogène, diminue les événements cardiovasculaires incidents chez des patients diabétiques de type 2.
- Published
- 2022
12. Established and novel gender dimorphisms in type 2 diabetes mellitus: Insights from a multiethnic cohort.
- Author
-
UCL - SSS/IREC/CARD - Pôle de recherche cardiovasculaire, UCL - SSS/IREC/EDIN - Pôle d'endocrinologie, diabète et nutrition, UCL - (SLuc) Service de pathologie cardiovasculaire, UCL - (SLuc) Service d'endocrinologie et de nutrition, Hermans, Michel, Ahn, Sylvie, Sadikot, Shaukat, Rousseau, Michel, UCL - SSS/IREC/CARD - Pôle de recherche cardiovasculaire, UCL - SSS/IREC/EDIN - Pôle d'endocrinologie, diabète et nutrition, UCL - (SLuc) Service de pathologie cardiovasculaire, UCL - (SLuc) Service d'endocrinologie et de nutrition, Hermans, Michel, Ahn, Sylvie, Sadikot, Shaukat, and Rousseau, Michel
- Abstract
BACKGROUND AND AIMS: In type 2 diabetes mellitus (T2DM), sexual dimorphisms modulate the natural histories of hyperglycemia, anthropophysical/cardiometabolic phenotype, and susceptibility to chronic micro and macrovascular complications. The purpose of this work was to revisit known or new dimorphisms within a multiethnic cohort. METHODS: Among 1238 T2DM patients, men (63%) were compared to women (37%), including leading ethnicities: Whites (67.4%; 542 men; 293 women); Maghrebians (9.4%; 62 men; 54 women); and Blacks (12.5%; 92 men; 63 women). RESULTS: Age, BMI, diabetes duration, insulin sensitivity, B-cell function loss, HbA1c, and hyperglycemia index were similar in both genders. All-cause microangiopathy and cerebrovascular disease did not differ between sexes. Women had significantly more retinopathy (27% vs. 21%) and men more microalbuminuria (25% vs. 19%), all-cause macroangiopathy (40% vs. 26%), CAD (29% vs. 17%) and PAD (11% vs. 6%). Among Blacks, sexual dimorphism in terms of retinopathy was more pronounced (24% in women vs. 11%), while there was no sexual dimorphism in all-cause macroangiopathy, CAD or PAD. B-cell function loss was faster among North African men (+15%), who also had more hepatic steatosis (+27%) than women. CONCLUSIONS: T2DM abolishes the CV protection provided by the female gender in Blacks. In White women, the loss of CV protection in diabetes is limited to cerebrovascular disease. In Black women, a markedly increased risk of retinopathy is present, despite glycemic exposure similat to men. Sexual dimorphisms do not affect glucose homeostasis and metabolic control in all ethnicities, except for lesser B-cell function loss in Maghrebian women.
- Published
- 2021
13. Heart-type fatty acid binding protein is related to severity and established cardiac biomarkers of heart failure
- Author
-
UCL - SSS/IREC/EDIN - Pôle d'endocrinologie, diabète et nutrition, UCL - (SLuc) Service de biochimie médicale, UCL - SSS/IREC/CARD - Pôle de recherche cardiovasculaire, UCL - (SLuc) Département cardiovasculaire, Gruson, Damien, Adamantidou, Christina, Ahn, Sylvie A., Rousseau, Michel F., UCL - SSS/IREC/EDIN - Pôle d'endocrinologie, diabète et nutrition, UCL - (SLuc) Service de biochimie médicale, UCL - SSS/IREC/CARD - Pôle de recherche cardiovasculaire, UCL - (SLuc) Département cardiovasculaire, Gruson, Damien, Adamantidou, Christina, Ahn, Sylvie A., and Rousseau, Michel F.
- Abstract
Objectives: To determine concentrations of heart-type fatty acid-binding protein (HFABP) in patients with heart failure with reduced ejection fraction (HFrEF) and its potential value for prognostic assessment. Methods: Circulating levels of HFABP were measured with an automated chemiluminescent immunoassay in 25 healthy volunteers and 60 HFrEF patients. Results: Concentrations of HFABP were significantly increased in heart failure patients in comparison to healthy volunteers. HFABP levels were significantly correlated to New York Heart Association classes and to established biomarkers of cardiac dysfunction and remodeling (amino-terminal pro-B-type natriuretic peptide [NT-proBNP], fibroblast growth factor 23, and galectin-3). HFABP concentrations were also predictive of cardiovascular (CV) death and combination with NT-proBNP might be synergistic for risk assessment. Conclusions: HFABP levels are increased in HFrEF patients, related to adverse CV outcomes, and might assist physicians for patient's management. © 2021 Damien Gruson et al., published by De Gruyter, Berlin/Boston.
- Published
- 2021
14. Lipid and cardiometabolic features of T2DM patients achieving stricter LDL-C and non-HDL-C targets in accordance with ESC/EAS 2019 guidelines.
- Author
-
UCL - SSS/IREC/CARD - Pôle de recherche cardiovasculaire, UCL - SSS/IREC/EDIN - Pôle d'endocrinologie, diabète et nutrition, UCL - (SLuc) Service de pathologie cardiovasculaire, UCL - (SLuc) Service d'endocrinologie et de nutrition, Hermans, Michel, Ahn, Sylvie, Rousseau, Michel, UCL - SSS/IREC/CARD - Pôle de recherche cardiovasculaire, UCL - SSS/IREC/EDIN - Pôle d'endocrinologie, diabète et nutrition, UCL - (SLuc) Service de pathologie cardiovasculaire, UCL - (SLuc) Service d'endocrinologie et de nutrition, Hermans, Michel, Ahn, Sylvie, and Rousseau, Michel
- Abstract
BACKGROUND: New recommendations call for lowering LDL-C < 55 mg/dL and non-HDL-C < 85 mg/dL in very-high cardiovascular risk (VH-CVR) patients with type 2 diabetes (T2DM). This study assessed the proportion of VH-CVR diabetics currently meeting these primary and secondary lipid targets, and which therapies/phenotypes predict combined goals achievement. METHODS: We analysed the cardiometabolic phenotype, use of lipid-modulatind drugs (LMD), pre- and post-LMD lipids levels, and CV complications among 1196 T2DM with high (n = 221; 18%) or VH-CVR (n = 975; 82%). Among the latter, the characteristics of combined lipid goal-achievers (n = 158) were compared to those of non-achievers (n = 817), with subgroup analyses of on-statin patients (n = 732) and those with established CVD taking statins (n = 362). Presence of statin-associated muscle symptoms (SAMS) was also recorded. RESULTS: 75% of VH-CVR patients were on statins. Both LDL-C and non-HDL-C goals were achieved by 16.2% of all VH-CVR, 19.3% of on-statin VH-CVR, and 24.3% of patients with established CVD taking statins. Achieving both targets was associated with high-intensity statins, specifically rosuvastatin, [statin + ezetimibe] combination, lower baseline LDL-C, smaller LDLs, lower TG and lipoprotein(a), and reduced metabolic syndrome frequency. SAMS reporting did not differ between achievers and non-achievers. CONCLUSIONS: More than 80% of patients are above targets. To bridge this gap, apart from treating more LMD-naive/refractory diabetics, one should consider for LDL-C to put most patients on high-intensity statins, more often with ezetimibe and, within statins, to switch preferably to rosuvastatin. As regards non-HDL-C, the off-target patients' phenotype suggests that intensifying lifestyle measures against metabolic syndrome should supplement current therapies.
- Published
- 2021
15. Lipoprotein(a) levels are doubled in left-handed patients with diabetes.
- Author
-
UCL - SSS/IREC/CARD - Pôle de recherche cardiovasculaire, UCL - SSS/IREC/EDIN - Pôle d'endocrinologie, diabète et nutrition, UCL - (SLuc) Service de pathologie cardiovasculaire, UCL - (SLuc) Service d'endocrinologie et de nutrition, Hermans, Michel, Ahn, Sylvie A, Rousseau, Michel, UCL - SSS/IREC/CARD - Pôle de recherche cardiovasculaire, UCL - SSS/IREC/EDIN - Pôle d'endocrinologie, diabète et nutrition, UCL - (SLuc) Service de pathologie cardiovasculaire, UCL - (SLuc) Service d'endocrinologie et de nutrition, Hermans, Michel, Ahn, Sylvie A, and Rousseau, Michel
- Abstract
Handedness is a tangible manifestation of cerebral motor lateralization. It is partly hereditary, it arises early in foetal life, and is modulated by intrauterine, perinatal and epigenetic factors. While the molecular bases of handedness have yet to be formally established, genetic studies have hinted at a polygenic origin partly under the control of molecular mechanisms establishing left–right body asymmetry. A previous report had found that non-right-handed (non-RH) patients with type 2 diabetes mellitus (T2DM) had better insulin sensitivity (IS) than their right-handed (RH) counterparts, which was unrelated to differences in obesity, body composition and physical activity. It was also observed that gastrointestinal intolerance to metformin was associated with a lower prevalence of ischaemic heart disease and with being left-handed (LH), whereas being non-RH was over-represented among metabolically-healthy normal-weight T2DM patients without the metabolic syndrome (MetS). Yet, there are virtually no data on lipids, lipoproteins or apolipoprotein (apo) levels as a function of motor laterality. For this reason, our present analysis was performed to determine whether laterality could modulate lipids/lipoproteins, including lipoprotein(a) [Lp(a)], in DM patients [...]
- Published
- 2020
16. Fatty Liver Linked to Reduced Frequency of Ocular Complications in T2DM
- Author
-
UCL - (SLuc) Service d'endocrinologie et de nutrition, Gninkoun, Comlan Jules, Ahn, Sylvie A., Amoussou-Guenou, K. Daniel, Bouenizabila, Evariste, Rousseau, Michel F., Hermans, Michel P., UCL - (SLuc) Service d'endocrinologie et de nutrition, Gninkoun, Comlan Jules, Ahn, Sylvie A., Amoussou-Guenou, K. Daniel, Bouenizabila, Evariste, Rousseau, Michel F., and Hermans, Michel P.
- Published
- 2020
17. Can viability assessment by DE-MRI predict survival in patients with multivessel disease and low ejection fraction? Influence of treatment strategies
- Author
-
Vanoverschelde Jean-Louis, Pasquet Agnès, Pouleur Anne-Catherine, de Waroux Jean-Benoit, Ahn Sylvie, Gerber Bernhard L, and Rousseau Michel
- Subjects
Diseases of the circulatory (Cardiovascular) system ,RC666-701 - Published
- 2011
- Full Text
- View/download PDF
18. Increased plasma myostatin in heart failure
- Author
-
Gruson, Damien, Ahn, Sylvie A., Ketelslegers, Jean-Marie, and Rousseau, Michel F.
- Published
- 2011
- Full Text
- View/download PDF
19. Additional Prognostic Value of 2D Right Ventricular Speckle-Tracking Strain for Prediction of Survival in Heart Failure and Reduced Ejection Fraction
- Author
-
Houard, Laura, primary, Benaets, Marie-Bénédicte, additional, de Meester de Ravenstein, Christophe, additional, Rousseau, Michel F., additional, Ahn, Sylvie A., additional, Amzulescu, Mihaela-Silvia, additional, Roy, Clotilde, additional, Slimani, Alisson, additional, Vancraeynest, David, additional, Pasquet, Agnès, additional, Vanoverschelde, Jean-Louis J., additional, Pouleur, Anne-Catherine, additional, and Gerber, Bernhard L., additional
- Published
- 2019
- Full Text
- View/download PDF
20. Additional Prognostic Value of 2D Right Ventricular Speckle-Tracking Strain for Prediction of Survival in Heart Failure and Reduced Ejection Fraction: A Comparative Study With Cardiac Magnetic Resonance
- Author
-
Houard, Laura, Benaets, Marie Bénédicte, de Meester de Ravenstein, Christophe, Rousseau, Michel F., Ahn, Sylvie A., Amzulescu, Mihaela Silvia, Roy, Clotilde, Slimani, Alisson, Vancraeynest, David, Pasquet, Agnes, Vanoverschelde, Jean Louis J., Pouleur, Anne Catherine, Gerber, Bernhard L., UCL - SSS/IREC/CARD - Pôle de recherche cardiovasculaire, UCL - (SLuc) Service de pathologie cardiovasculaire, and Cardiology
- Subjects
Survival ,Radiology Nuclear Medicine and imaging ,Speckle-tracking echocardiography ,heart failure ,Heart failure ,CMR ,Cardiology and Cardiovascular Medicine ,survival ,speckle-tracking echocardiography - Abstract
OBJECTIVES: This study sought to compare the prognostic value of 2-dimensional (2D) right ventricular (RV) speckle tracking (STE) against cardiac magnetic resonance (CMR) RV ejection fraction (EF) and feature tracking (FT) and conventional echocardiographic parameters on overall and cardiovascular (CV) survival in patients with heart failure with reduced EF (HFrEF). BACKGROUND: Prior works showed that RV systolic function predicts prognosis in HFrEF. 2D RVSTE had recently been proposed as new echocardiographic method to evaluate RV dysfunction. METHODS: A total of 266 patients with HFrEF (mean LVEF 23 ± 7%, 60 ± 14 years of age; 29% women) underwent RV function assessment using CMR and 2D echocardiography and were followed for a primary endpoint of overall death and secondary endpoint of CV death. RESULTS: Average CMR-RVEF was 42 ± 15%, average STE RV global longitudinal strain (STE-RVGLS) was -18.0 ± 4.9%, and average CMR-FT-RVGLS was -11.8 ± 4.3%. After a median follow-up of 4.7 years, 102 patients died, 84 of a CV cause. RVEF, FT-RVGLS, tricuspid annulus plane systolic excursion (TAPSE), fractional area change (FAC), and STE-RVGLS were significant univariate predictors of overall and cardiac death. In multivariate Cox regression, age, ischemic etiology, diabetes, New York Heart Association functional class III to IV, and beta-blocker treatment were independent clinical predictors of overall mortality. CMR-RVEF (chi-square to enter = 3.9; p < 0.05), FT-RVGLS (chi-square to enter 3.7; p = 0.05), FAC (chi-square to enter 6.2; p = 0.02), and TAPSE (chi-square to enter = 4.1; p = 0.04) provided additional prognostic value over these baseline parameters, but the additional predictive value of STE-RVGLS (chi-square to enter = 10.8; p < 0.001) was significantly (p < 0.05) higher than the other tests. Additional hazard ratio to predict overall mortality was 2.5 (95% confidence interval [CI]: 1.6 to 3.9) for STE-RVGLS 15 mm, 1.6 (95% CI: 1.02 to 2.49) for FAC >39%, 1.93 (95% CI: 1.25 to 2.99) for RVEF >41%, and 1.87 (95% CI: 1.10 to 3.19) for CMR-FT-RVGLS
- Published
- 2019
21. Additional Prognostic Value of 2D Right Ventricular Speckle-Tracking Strain for Prediction of Survival in Heart Failure and Reduced Ejection Fraction: A Comparative Study With Cardiac Magnetic Resonance.
- Author
-
UCL - SSS/IREC/CARD - Pôle de recherche cardiovasculaire, UCL - (SLuc) Service de pathologie cardiovasculaire, Houard, Laura, Benaets, Marie-Bénédicte, de Meester de Ravenstein, Christophe, Rousseau, Michel, Ahn, Sylvie, Amzulescu, Mihaela Silvia, Roy, Clotilde, Slimani, Alisson, Vancraeynest, David, Pasquet, Agnes, Vanoverschelde, Jean-Louis, Pouleur, Anne-Catherine, Gerber, Bernhard, UCL - SSS/IREC/CARD - Pôle de recherche cardiovasculaire, UCL - (SLuc) Service de pathologie cardiovasculaire, Houard, Laura, Benaets, Marie-Bénédicte, de Meester de Ravenstein, Christophe, Rousseau, Michel, Ahn, Sylvie, Amzulescu, Mihaela Silvia, Roy, Clotilde, Slimani, Alisson, Vancraeynest, David, Pasquet, Agnes, Vanoverschelde, Jean-Louis, Pouleur, Anne-Catherine, and Gerber, Bernhard
- Abstract
OBJECTIVES: This study sought to compare the prognostic value of 2-dimensional (2D) right ventricular (RV) speckle tracking (STE) against cardiac magnetic resonance (CMR) RV ejection fraction (EF) and feature tracking (FT) and conventional echocardiographic parameters on overall and cardiovascular (CV) survival in patients with heart failure with reduced EF (HFrEF). BACKGROUND: Prior works showed that RV systolic function predicts prognosis in HFrEF. 2D RVSTE had recently been proposed as new echocardiographic method to evaluate RV dysfunction. METHODS: A total of 266 patients with HFrEF (mean LVEF 23 ± 7%, 60 ± 14 years of age; 29% women) underwent RV function assessment using CMR and 2D echocardiography and were followed for a primary endpoint of overall death and secondary endpoint of CV death. RESULTS: Average CMR-RVEF was 42 ± 15%, average STE RV global longitudinal strain (STE-RVGLS) was -18.0 ± 4.9%, and average CMR-FT-RVGLS was -11.8 ± 4.3%. After a median follow-up of 4.7 years, 102 patients died, 84 of a CV cause. RVEF, FT-RVGLS, tricuspid annulus plane systolic excursion (TAPSE), fractional area change (FAC), and STE-RVGLS were significant univariate predictors of overall and cardiac death. In multivariate Cox regression, age, ischemic etiology, diabetes, New York Heart Association functional class III to IV, and beta-blocker treatment were independent clinical predictors of overall mortality. CMR-RVEF (chi-square to enter = 3.9; p < 0.05), FT-RVGLS (chi-square to enter 3.7; p = 0.05), FAC (chi-square to enter 6.2; p = 0.02), and TAPSE (chi-square to enter = 4.1; p = 0.04) provided additional prognostic value over these baseline parameters, but the additional predictive value of STE-RVGLS (chi-square to enter = 10.8; p < 0.001) was significantly (p < 0.05) higher than the other tests. Additional hazard ratio to predict overall mortality was 2.5 (95% confidence interval [CI]: 1.6 to 3.9) for STE-RVGLS <-19%, 2.15 (95% CI: 1.34 to 3.43) for TAPSE >15 mm, 1.
- Published
- 2019
22. Increased CRP: An extended biomarker of microvascular risk in men with type 2 diabetes.
- Author
-
UCL - SSS/IREC/CARD - Pôle de recherche cardiovasculaire, UCL - SSS/IREC/EDIN - Pôle d'endocrinologie, diabète et nutrition, UCL - (SLuc) Service de pathologie cardiovasculaire, UCL - (SLuc) Service d'endocrinologie et de nutrition, Hermans, Michel, Ahn, Sylvie, Rousseau, Michel, UCL - SSS/IREC/CARD - Pôle de recherche cardiovasculaire, UCL - SSS/IREC/EDIN - Pôle d'endocrinologie, diabète et nutrition, UCL - (SLuc) Service de pathologie cardiovasculaire, UCL - (SLuc) Service d'endocrinologie et de nutrition, Hermans, Michel, Ahn, Sylvie, and Rousseau, Michel
- Abstract
BACKGROUND: The usefulness of C-reactive protein (CRP) to predict cardiovascular disease (CVD) in type 2 diabetes (T2DM) remains controversial. As many factors linked to obesity can modulate CRP in T2DM, we comprehensively revisited the cardiometabolic phenotype of patients with normal or raised CRP, taking into account the sexual dimorphism of its serum value. METHODS: 1005 T2DM patients (651 males, 354 females; macroangiopathy 38%; coronary artery disease 26%; microangiopathy 47%) were divided depending on whether CRP level was ≤ or >3 mg/L. Thirty percent of men (n = 195) and 39% of women (n = 137) had raised CRP. Their cardiometabolic phenotype and presence of micro- and macrovascular complications were compared to those with normal CRP. RESULTS: In both gender, patients with elevated CRP had higher body mass index, waist circumference, fat mass, visceral fat, insulinemia, HbA1c, and lower muscle mass and insulin sensitivity. They had more atherogenic dyslipidemia, higher non-HDL-C and apolipoprotein B100, and more lipoprotein(a) (+59% in men and +38% in women). In both sexes, there was no difference between patients with normal or high CRP regarding overall macroangiopathy (42% vs. 45% [men]; 27% vs. 28% [women]), coronary and peripheral artery disease, or stroke. Only in men, microangiopathy was more prevalent when CRP was raised (61% vs 44%; p < 0.0001). CONCLUSIONS: This study shows major sex-related differences in microangiopathies in T2DM patients with high CRP levels. The latter are unrelated to prevalent CVD despite an unfavorable metabolic phenotype. By contrast, increased CRP may represent an extended biomarker of microvascular risk in men with T2DM.
- Published
- 2019
23. The atherogenic dyslipidemia ratio [log(TG)/HDL-C] is associated with residual vascular risk, beta-cell function loss and microangiopathy in type 2 diabetes females
- Author
-
Hermans Michel P, Ahn Sylvie A, and Rousseau Michel F
- Subjects
HDL-C ,Triglycerides ,Cardiovascular risk ,Microangiopathy ,β-cell function ,Hyperbolic product ,Gender ,Diabetes ,Nutritional diseases. Deficiency diseases ,RC620-627 - Abstract
Abstract Background Atherogenic dyslipidemia (AD), defined as low HDL-C plus elevated triglycerides (TG), comorbid to T2DM, increases cardiometabolic risk for CAD even when LDL-C is at target. In T2DM males, AD was shown to correlate with β-cell function loss, yet it is not established whether this applies across gender. Aim To establish the prevalence and severity of AD in T2DM females, and to determine how it relates to cardiometabolic phenotype, glucose homeostasis, micro- and macrovascular complications, and 10-year absolute CV risk (UKPDS Risk Engine). Methods 340 T2DM females were ranked according to quintiles (Q) of the continuous variable log(TG)/HDL-C, with AD prevalence defined as HDL-C -1 plus TG ≥150 mg.dL-1, and β-cell function assessed with HOMA. Results AD prevalence was 35%; mean HDL-C and TG were 52 (15) and 160 (105) mg.dL-1. AD was significantly related to central fat, metabolic syndrome, sedentarity and skeletal sarcopenia, as well as to hsCRP, fibrinogen, uric acid, cystatin-C, Big ET-1, and 10-year UKPDS CV risk. AD correlated stepwise with lower β-cell function and hyperbolic product, and with accelerated loss of residual insulin secretion, higher HbA1c and prevalent microangiopathy. Conclusions log(TG)/HDL-C is a simple means to grade AD and residual macrovascular risk in T2DM females. This ratio associates with major non-LDL cardiometabolic variables and ranks predicted CAD risk. In addition, log(TG)/HDL-C identifies worsening glucose homeostasis, poorer glycemic control, and prevalent microangiopathy.
- Published
- 2012
- Full Text
- View/download PDF
24. Non-HDL-cholesterol as valid surrogate to apolipoprotein B100 measurement in diabetes: Discriminant Ratio and unbiased equivalence
- Author
-
Ahn Sylvie A, Sacks Frank M, Hermans Michel P, and Rousseau Michel F
- Subjects
Diseases of the circulatory (Cardiovascular) system ,RC666-701 - Abstract
Abstract Background Apolipoprotein B100 (apoB) is a superior indicator of CV risk than total or LDL-C. Non-HDL-C represents a simple surrogate for apoB in hypertriglyceridemic and/or T2DM patients. ApoB and non-HDL-C show high correlation, although the degree of mutual concordance remains debated in CV risk evaluation. Objectives We used the Discriminant Ratio (DR) methodology to compare the performance of non-HDL-C with that of apoB to rank diabetic patients according to dyslipidemia and to establish the underlying relationship between these variables taking measurement noise and intra-/intersubject variation into account, and to derive an unbiased equivalence equation. Methods Fasting total C, HDL-C, apoB and triglycerides were measured in 45 diabetic patients. The DR of the underlying between-subject standard deviation (SD) to the within-subject SD was calculated from duplicates. Correlation coefficients between pairs were adjusted to include an estimate of the underlying correlation. Results Mean values [day 1 (1SD)] were 143 (36) mg/dl (non-HDL-C) and 98 (24) mg/dl (apoB). The DR's of both parameters were similar (1.76 and 1.83) (p = 0.83). Pearson's product-moment correlation coefficient between tests was very high (0.94), reaching unity (1.00) after attenuation adjustment. The unbiased equation of equivalence relating apoB to non-HDL-C had a slope of 0.65 and an intercept of 6.3 mg/dl. Conclusions The discrimination power of non-HDL-C is similar to that of apoB to rank diabetic patients according to atherogenic cholesterol and lipoprotein burden. Since true correlation between variables reached unity, non-HDL-C may provide not only a metabolic surrogate but also a candidate biometrical equivalent to apoB, as non-HDL-C calculation is readily available.
- Published
- 2011
- Full Text
- View/download PDF
25. log(TG)/HDL-C is related to both residual cardiometabolic risk and β-cell function loss in type 2 diabetes males
- Author
-
Ahn Sylvie A, Hermans Michel P, and Rousseau Michel F
- Subjects
Diseases of the circulatory (Cardiovascular) system ,RC666-701 - Abstract
Abstract Background T2DM is associated with atherogenic dyslipidemia (AD), defined as decreased HDL-C plus raised triglycerides (TG). AD confers increased risk for CAD, even when LDL-C is at target. AD is rarely assessed due to lack of screening methods consensus. Aim To establish the prevalence and severity of AD from log(TG)/HDL-C in T2DM males, and to determine how it relates to cardiometabolic phenotype, glucose homeostasis, micro- and macrovascular complications, and 10-year UKPDS CV risk. Methods 585 T2DM males divided according to quintiles (Q) of log(TG)/HDL-C. AD prevalence defined as HDL-C -1 plus TG ≥150 mg.dL-1. β-cell function assessed with HOMA. Results Mean HDL-C and TG were 44 (13) and 204 (155) mg.dL-1. AD prevalence was 35%. AD correlated with lower β-cell function, with accelerated loss of insulin secretion, and with poorer HbA1c levels. AD was related to a high prevalence of CAD, and also to 10-year absolute CAD risk. Conclusions log(TG)/HDL-C is a simple means to estimate AD and the residual CV risk it confers in T2DM. AD closely associates with major cardiometabolic and glucose homeostasis determinants and poorer metabolic control. The ratio also relates to macroangiopathy prevalence and ranks future CAD risk, and is well-suited to capture non-LDL-related macrovascular residual risk and major glycemic determinants.
- Published
- 2010
- Full Text
- View/download PDF
26. Beneficial neurohormonal profile of spironolactone in severe congestive heart failure: Results from the RALES neurohormonal substudy
- Author
-
Rousseau, Michel F, Gurné, Olivier, Duprez, Daniel, Van Mieghem, Walter, Robert, Annie, Ahn, Sylvie, Galanti, Laurence, and Ketelslegers, Jean-Marie
- Published
- 2002
- Full Text
- View/download PDF
27. Lipid disorders in diabetes
- Author
-
UCL - SSS/IREC/CARD - Pôle de recherche cardiovasculaire, UCL - SSS/IREC/EDIN - Pôle d'endocrinologie, diabète et nutrition, UCL - (SLuc) Service de pathologie cardiovasculaire, UCL - (SLuc) Service d'endocrinologie et de nutrition, Hermans, Michel, Ahn, Sylvie, Rousseau, Michel, UCL - SSS/IREC/CARD - Pôle de recherche cardiovasculaire, UCL - SSS/IREC/EDIN - Pôle d'endocrinologie, diabète et nutrition, UCL - (SLuc) Service de pathologie cardiovasculaire, UCL - (SLuc) Service d'endocrinologie et de nutrition, Hermans, Michel, Ahn, Sylvie, and Rousseau, Michel
- Published
- 2018
28. Incremental value of intact fibroblast growth factor 23 to natriuretic peptides for long-term risk estimation of heart failure patients.
- Author
-
UCL - SSS/IREC/EDIN - Pôle d'endocrinologie, diabète et nutrition, UCL - (SLuc) Service de biochimie médicale, Gruson, Damien, Carbone, Vincenzo, Feracin, Benjamin, Ahn, Sylvie A, Rousseau, Michel F, UCL - SSS/IREC/EDIN - Pôle d'endocrinologie, diabète et nutrition, UCL - (SLuc) Service de biochimie médicale, Gruson, Damien, Carbone, Vincenzo, Feracin, Benjamin, Ahn, Sylvie A, and Rousseau, Michel F
- Abstract
Fibroblast growth factor 23 (FGF-23), a key hormone for the regulation of the phosphorus homeostasis, has also several direct effects on cardiac function. In heart failure (HF), the increase of FGF-23 participates to cardiac hypertrophy and remodeling. Measurement of the intact, biologically active hormone is now available. We determined intact FGF-23 in HF patients with reduced ejection fraction and assess its prognosis value for cardiovascular death over a long-term follow-up. We observed that intact FGF-23 is an independent predictor of cardiovascular death in HF patients and provides added value to the standard of care, natriuretic peptide, for risk estimation.
- Published
- 2018
29. Lipoprotein(a) Levels Are Twice as High in Left-Handed T2DM Patients
- Author
-
HERMANS, MICHEL P., primary, AHN, SYLVIE A., additional, and ROUSSEAU, MICHEL F., additional
- Published
- 2018
- Full Text
- View/download PDF
30. PROGNOSTIC VALUE OF RIGHT VENTRICULAR SYSTOLIC DYSFUNCTION IN HEART FAILURE WITH REDUCED EJECTION FRACTION
- Author
-
Pouleur, Anne-Catherine, primary, Bénats, Marie-Bénédicte, additional, Ahn, Sylvie A., additional, de Meester, Christophe, additional, Amzulescu, Mihaela, additional, Vancraeynest, David, additional, Pasquet, Agnès, additional, Vanoverschelde, Jean-Louis, additional, Gerber, Bernhard, additional, and Rousseau, Michel, additional
- Published
- 2018
- Full Text
- View/download PDF
31. Head to head comparison of intact and C-terminal fibroblast growth factor 23 in heart failure patients with reduced ejection fraction
- Author
-
UCL - SSS/IREC/EDIN - Pôle d'endocrinologie, diabète et nutrition, UCL - SSS/IREC/CARD - Pôle de recherche cardiovasculaire, UCL - (SLuc) Service de pathologie cardiovasculaire, UCL - (SLuc) Service de biochimie médicale, Gruson, Damien, Ferracin, Benjamin, Ahn, Sylvie A., Rousseau, Michel, UCL - SSS/IREC/EDIN - Pôle d'endocrinologie, diabète et nutrition, UCL - SSS/IREC/CARD - Pôle de recherche cardiovasculaire, UCL - (SLuc) Service de pathologie cardiovasculaire, UCL - (SLuc) Service de biochimie médicale, Gruson, Damien, Ferracin, Benjamin, Ahn, Sylvie A., and Rousseau, Michel
- Published
- 2017
32. Efficacy and safety of a combination of red yeast rice and olive extract in hypercholesterolemic patients with and without statin-associated myalgia.
- Author
-
UCL - SSS/IREC/CARD - Pôle de recherche cardiovasculaire, UCL - SSS/IREC/EDIN - Pôle d'endocrinologie, diabète et nutrition, UCL - (SLuc) Service de pathologie cardiovasculaire, UCL - (SLuc) Service d'endocrinologie et de nutrition, Tshongo Muhindo, Christian, Ahn, Sylvie, Rousseau, Michel, Dierckxsens, Yvan, Hermans, Michel, UCL - SSS/IREC/CARD - Pôle de recherche cardiovasculaire, UCL - SSS/IREC/EDIN - Pôle d'endocrinologie, diabète et nutrition, UCL - (SLuc) Service de pathologie cardiovasculaire, UCL - (SLuc) Service d'endocrinologie et de nutrition, Tshongo Muhindo, Christian, Ahn, Sylvie, Rousseau, Michel, Dierckxsens, Yvan, and Hermans, Michel
- Abstract
Cholesfytol, a lipid-lowering dietary supplement with antioxidant and anti-atherosclerotic properties, combines red yeast rice (RYR) and olive extract (5mg hydroxytyrosol equivalent) and represents an alternative for patients who do not wish or are unable to use chemical statins, including individuals with previous statin-associated muscle symptoms (SAMS). A 2-months observational non-randomized study was performed to evaluate the efficacy, tolerance and safety of Cholesfytol (1 tablet/day) in 642 hypercholesterolemic patients (mean age: 59 yrs; total cholesterol (TC) ≥200; LDL-C ≥140mg/dl). Patients were followed by 126 GPs, and included irrespective of SAMS history and/or diabetes. None of the patients were taking statins or other lipid-modifying therapy at inclusion. At baseline, 26% had fasting glucose >100 ≤125mg/dL, and 5% >125mg/dL; 32% (n=194) had a SAMS history; and 21% had atherogenic dyslipidemia (AD). In the entire cohort, pre-treatment TC; non-HDL-C; LDL-C; and TG were 259; 200; 168; 158mg/dL, respectively, and decreased significantly on treatment (-17.5% (TC) and -23.3% (LDL-C)). Fasting glucose and HbA decreased between visits. The reduction in lipids was greater in patients with higher values at baseline. For comparable pre-treatment values, patients with SAMS history had reductions in TC, LDL-C, non-HDL-C, and apoB slightly less than patients without myalgia. AD patients had greater on-treatment decrease in TG. Overall, 13 patients reported minor side-effects, and 4 patients reporting myalgia had antecedent SAMS. In conclusion, a substantial decrease in LDL-C was obtained with a combination of RYR and olive extract in high-risk hypercholesterolemic patients, without inducing new-onset SAMS.
- Published
- 2017
33. The mixed benefit of low lipoprotein(a) in type 2 diabetes
- Author
-
Hermans, Michel P., primary, Ahn, Sylvie A., additional, and Rousseau, Michel F., additional
- Published
- 2017
- Full Text
- View/download PDF
34. Elevation of plasma oncostatin M in heart failure
- Author
-
Gruson, Damien, primary, Ferracin, Benjamin, additional, Ahn, Sylvie A, additional, and Rousseau, Michel F, additional
- Published
- 2017
- Full Text
- View/download PDF
35. Right Ventricular Systolic Dysfunction Assessed by Cardiac Magnetic Resonance Is a Strong Predictor of Cardiovascular Death After Coronary Bypass Grafting
- Author
-
UCL - SSS/IREC/CARD - Pôle de recherche cardiovasculaire, UCL - (SLuc) Service de pathologie cardiovasculaire, Pouleur, Anne-Catherine, Rousseau, Michel F., Ahn, Sylvie A., Amzulescu, Mihaela Silvia, Demeure, Fabian, de Meester de Ravenstein, Christophe, Vancraeynest, David, Pasquet, Agnes, Vanoverschelde, Jean-Louis, Gerber, Bernhard, UCL - SSS/IREC/CARD - Pôle de recherche cardiovasculaire, UCL - (SLuc) Service de pathologie cardiovasculaire, Pouleur, Anne-Catherine, Rousseau, Michel F., Ahn, Sylvie A., Amzulescu, Mihaela Silvia, Demeure, Fabian, de Meester de Ravenstein, Christophe, Vancraeynest, David, Pasquet, Agnes, Vanoverschelde, Jean-Louis, and Gerber, Bernhard
- Abstract
BACKGROUND: Limited data are available regarding the prognostic value of right ventricular (RV) systolic dysfunction (RVSD) in patients with coronary artery disease. Our objective was to evaluate the effect of RVSD assessed by cardiac magnetic resonance on survival of patients with low left ventricular (LV) ejection fraction (EF) undergoing coronary bypass grafting (CABG). METHODS: We prospectively assessed overall and cardiovascular death of 107 consecutive patients (94 men; age, 66 ± 10 years) undergoing CABG who had a LVEF of 0.35 or less by cardiac magnetic resonance before CABG. RESULTS: Mean LVEF was 0.25 ± 0.07, and mean RVEF was 0.46 ± 0.16. RVSD, defined by RVEF of 0.35 or less, was present in 32 patients (30%). In-hospital mortality rate (n = 8) was significantly higher in patients with RVSD (18.7% vs 2.7%, p = 0.004). Over a median follow-up of 4.7 years, 44 patients died, 33 of a cardiovascular cause. The primary end point of cardiovascular death was reached by 15 of 32 patients with RVSD and 18 of 75 patients without RVSD (47% vs 24%, p = 0.019). Univariate survival analysis showed that age, New York Heart Association Functional Classification, diabetes, estimated glomerular filtration rate, LVEF, LV indexed end-diastolic volume, RVEF, RV indexed end-diastolic volume, RV systolic function, and The Society of Thoracic Surgeons risk score were independent predictors of the primary end point of cardiovascular death. By multivariable analysis, the Society of Thoracic Surgeons risk score (hazard ratio, 1.32; 95% confidence interval, 1.13 to 1.55; p = 0.001) and RVSD (hazard ratio, 2.14; 95% confidence interval, 1.06 to 4.31; p = 0.034) remained significant independent predictors of cardiovascular death. CONCLUSIONS: RVSD strongly and independently predicts cardiovascular death in patients with coronary artery disease and low EF undergoing CABG. Evaluation of RV function should thus be part of preoperative evaluation of such patients.
- Published
- 2016
36. The normal-weight type 2 diabetes phenotype revisited.
- Author
-
UCL - (SLuc) Service d'endocrinologie et de nutrition, UCL - (SLuc) Service de pathologie cardiovasculaire, UCL - SSS/IREC/CARD - Pôle de recherche cardiovasculaire, UCL - SSS/IREC/EDIN - Pôle d'endocrinologie, diabète et nutrition, Hermans, Michel, Amoussou-Guenou, K Daniel, Bouenizabila, Evariste, Sadikot, Shaukat S, Ahn, Sylvie, Rousseau, Michel, UCL - (SLuc) Service d'endocrinologie et de nutrition, UCL - (SLuc) Service de pathologie cardiovasculaire, UCL - SSS/IREC/CARD - Pôle de recherche cardiovasculaire, UCL - SSS/IREC/EDIN - Pôle d'endocrinologie, diabète et nutrition, Hermans, Michel, Amoussou-Guenou, K Daniel, Bouenizabila, Evariste, Sadikot, Shaukat S, Ahn, Sylvie, and Rousseau, Michel
- Abstract
BACKGROUND: Type 2 diabetes (T2DM) is associated with obesity, insulin resistance and the metabolic syndrome (MetS). In non-diabetic populations, features of metabolic obesity (MO) are observed in a minority of normal-weight (NW) subjects. The cardiometabolic status of metabolically obese but normal-weight (MONW) individuals has not yet been phenotyped in T2DM. PATIENTS AND METHODS: Prevalence and features of MONW were analyzed in 1244 T2DM patients, in whom MONW was identified as a BMI <25.0 and a MetS score ≥3/5. Among NW (n=262; 21%), those without MetS (n=152; NW-MetS[-]) were compared to NW-MetS[+] (n=110; i.e. 42% of NW and 9% of all T2DM). RESULTS: There were no differences between groups in age; gender; diabetes duration; smoking; BP; and LDL-C. NW-MetS[+] had higher BMI; waist; fat mass; visceral fat; liver steatosis and HbA1c, and lower insulin sensitivity. Non-right-handedness was twice-higher (18%) in NW-MetS[-]. NW-MetS[+] had higher apoB100 and triglycerides, and lower HDL-C and LDL size. Macroangiopathy was present in 39% of NW-MetS[+] vs. 22% of NW-MetS[-], as coronary (23% vs. 14%) or peripheral artery disease (14% vs. 5%) and TIA/stroke (15% vs. 7%). Microangiopathy was present in 54% of NW-MetS[+] vs. 32% of NW-MetS[-], as retinopathy (25% vs. 13%); neuropathy (29% vs. 18%); and albuminuria (39% vs. 20%). CONCLUSIONS: MONW among T2DM represents a significant minority (about 1 in 10). Their cardiometabolic phenotype deserves attention due to multiple comorbidities, including a twice-higher prevalence of micro-/macrovascular damage in patients wrongly perceived at lower risk due to normal BMI. Unexpectedly, non-right-handedness was over-represented among metabolically healthy patients
- Published
- 2016
37. Right Ventricular Systolic Dysfunction Assessed by Cardiac Magnetic Resonance Is a Strong Predictor of Cardiovascular Death After Coronary Bypass Grafting
- Author
-
Pouleur, Anne-Catherine M., primary, Rousseau, Michel F., additional, Ahn, Sylvie A., additional, Amzulescu, Mihaela, additional, Demeure, Fabian, additional, de Meester, Christophe, additional, Vancraeynest, David, additional, Pasquet, Agnès, additional, Vanoverschelde, Jean-Louis, additional, and Gerber, Bernhard L., additional
- Published
- 2016
- Full Text
- View/download PDF
38. LONG-TERM EFFECT OF EARLY ENALAPRIL THERAPY ON CAUSES OF DEATH IN PATIENTS WITH LEFT VENTRICULAR DYSFUNCTION: A 27-YEAR FOLLOW-UP OF SOLVD IN BELGIUM
- Author
-
Rousseau, Michel F., primary, Jong, Philip, additional, Ahn, Sylvie A., additional, and Pouleur, Hubert, additional
- Published
- 2016
- Full Text
- View/download PDF
39. Multiple biomarker strategy based on parathyroid hormone and natriuretic peptides testing for improved prognosis of chronic heart failure
- Author
-
UCL - (SLuc) Service de biochimie médicale, UCL - SSS/IREC/EDIN - Pôle d'endocrinologie, diabète et nutrition, UCL - (SLuc) Service de pathologie cardiovasculaire, Gruson, Damien, Ahn, Sylvie A., Rousseau, Michel, UCL - (SLuc) Service de biochimie médicale, UCL - SSS/IREC/EDIN - Pôle d'endocrinologie, diabète et nutrition, UCL - (SLuc) Service de pathologie cardiovasculaire, Gruson, Damien, Ahn, Sylvie A., and Rousseau, Michel
- Abstract
Biomarkers offer new perspectives for a more personalized management of patients with heart failure (HF). Hyperparathyroidism is common in HF patients and parathyroid hormone (PTH) testing might provide added value for the prognostication of HF patients. Our objectives were therefore to determine the efficiency of multiple biomarker strategy based on PTH and natriuretic peptides measurement for the risk stratification of patients with HF. Circulating concentrations of bioactive PTH 1-84 and natriuretic peptides, B-type natriuretic peptide (BNP) and N-terminal proBNP (NT-proBNP), were measured with automated immunoassays in 45 healthy individuals and 137 HF patients with reduced left ventricular ejection fraction. Circulating levels of PTH 1-84 and natriuretic peptides were significantly increased in HF patients in comparison to HF patients. Over a long-term follow-up, baseline PTH 1-84 levels were related to the risk of cardiovascular death. Furthermore, in multiple biomarker approach, PTH measurement was additive to BNP and NT-proBNP testing for the cardiovascular risk assessment of HF patients. In conclusion, the combination of PTH 1-84 and natriuretic peptides testing improves the prognostication of HF patients and might allowed more personalized approach for risk stratification and treatment selection in HF patients.
- Published
- 2015
40. Baseline diabetes as a way to predict CV outcomes in a lipid-modifying trial: A meta-analysis of 330,376 patients from 47 landmark studies
- Author
-
UCL - (SLuc) Service d'endocrinologie et de nutrition, UCL - SSS/IREC/CARD - Pôle de recherche cardiovasculaire, UCL - SSS/IREC/EDIN - Pôle d'endocrinologie, diabète et nutrition, UCL - (SLuc) Service de pathologie cardiovasculaire, Hermans, Michel, Bouenizabila, Evariste, Amoussou-guenou, Daniel K., Ahn, Sylvie A., Rousseau, Michel, UCL - (SLuc) Service d'endocrinologie et de nutrition, UCL - SSS/IREC/CARD - Pôle de recherche cardiovasculaire, UCL - SSS/IREC/EDIN - Pôle d'endocrinologie, diabète et nutrition, UCL - (SLuc) Service de pathologie cardiovasculaire, Hermans, Michel, Bouenizabila, Evariste, Amoussou-guenou, Daniel K., Ahn, Sylvie A., and Rousseau, Michel
- Abstract
Background: Diabetes is a major cardiovascular risk factor. However, its influence on the rate of occurrence of cardiovascular (CV) events during a clinical trial that included a diabetes subgroup has not yet been quantified. Aims: To establish equations relating baseline diabetes prevalence and incident CV events, based on comparator arms data of major lipid-modifying trials. Methods: Meta-analysis of primary outcomes (PO) rates of key prospective trials, for which the baseline proportion of diabetics was reported, including studies having specifically reported CV outcomes within their diabetic subgroups. Results: 47 studies, representing 330,376 patients (among whom 124,115 diabetics), were analyzed as regards the relationship between CV outcomes rates (including CHD) and the number of diabetics enrolled. Altogether, a total of 18,445 and 16,156 events occurred in the comparator and treatment arms, respectively. There were significant linear relationships between diabetes prevalence and both PO and CHD rates (%/year): y = 0.0299*x + 3.12 [PO] (p = 0.0128); and y = 0.0531*x + 1.54 [CHD] (p = 0.0094), baseline diabetes predicting PO rates between 3.12 %/year (no diabetic included) and 6.11 %/year (all patients diabetic); and CHD rates between 1.54 %/year (no diabetic) and 6.85 %/year (all patients diabetic). The slopes of the equations did not differ according to whether they were derived from primary or secondary prevention trials. Conclusions: Absolute and relative CV risk associated with diabetes at inclusion can be readily predicted using linear equations relating diabetes prevalence to primary outcomes or CHD rates.
- Published
- 2015
41. Comparison of fibroblast growth factor 23, soluble ST2 and Galectin-3 for prognostication of cardiovascular death in heart failure patients
- Author
-
UCL - SSS/IREC/CARD - Pôle de recherche cardiovasculaire, UCL - SSS/IREC/EDIN - Pôle d'endocrinologie, diabète et nutrition, UCL - (SLuc) Service de pathologie cardiovasculaire, UCL - (SLuc) Service de biochimie médicale, Gruson, Damien, Ferracin, Benjamin, Ahn, Sylvie A., Rousseau, Michel, UCL - SSS/IREC/CARD - Pôle de recherche cardiovasculaire, UCL - SSS/IREC/EDIN - Pôle d'endocrinologie, diabète et nutrition, UCL - (SLuc) Service de pathologie cardiovasculaire, UCL - (SLuc) Service de biochimie médicale, Gruson, Damien, Ferracin, Benjamin, Ahn, Sylvie A., and Rousseau, Michel
- Published
- 2015
42. Prognostic Impact of Hypertrabeculation and Noncompaction Phenotype in Dilated Cardiomyopathy: A CMR Study.
- Author
-
UCL - SSS/IREC/CARD - Pôle de recherche cardiovasculaire, UCL - (SLuc) Service de pathologie cardiovasculaire, Amzulescu, Mihaela Silvia, Rousseau, Michel F, Ahn, Sylvie A, Boileau, Laurianne, de Meester de Ravenstein, Christophe, Vancraeynest, David, Pasquet, Agnes, Vanoverschelde, Jean-Louis, Pouleur, Anne-Catherine, Gerber, Bernhard, UCL - SSS/IREC/CARD - Pôle de recherche cardiovasculaire, UCL - (SLuc) Service de pathologie cardiovasculaire, Amzulescu, Mihaela Silvia, Rousseau, Michel F, Ahn, Sylvie A, Boileau, Laurianne, de Meester de Ravenstein, Christophe, Vancraeynest, David, Pasquet, Agnes, Vanoverschelde, Jean-Louis, Pouleur, Anne-Catherine, and Gerber, Bernhard
- Abstract
OBJECTIVES: The purpose of this study was to evaluate the impact of hypertrabeculation and left ventricular (LV) myocardial noncompaction phenotype by cardiac magnetic resonance (CMR) on outcomes of patients with nonischemic dilated cardiomyopathy (DCM). BACKGROUND: Myocardial trabeculations and noncompaction are increasingly observed in patients with DCM, but their prognostic impact remains unknown. METHODS: We prospectively evaluated outcomes of 162 consecutive patients (102 men; age 55 ± 15 years; ejection fraction [EF] 25 ± 8%) with DCM undergoing CMR. The amount of noncompaction was quantified as noncompacted/compacted (NC/C) length in the long-axis view and as the ratio of NC/C mass in the short-axis view and compared against 48 healthy control subjects (age 60 ± 10 years). RESULTS: Fifty-eight DCM patients (36%) had NC/C length ≥2.3, and 71 (44%) had NC/C mass greater than the 95% confidence interval (CI) of control subjects. NC/C length and NC/C mass did not correlate with any clinical, echocardiographic, or CMR parameters. Over a 3.4-year median follow-up, 29 patients experienced major adverse cardiovascular events (MACE) (12 cardiovascular deaths, 8 heart transplantations, 4 LV assist device implantations, and 5 resuscitated cardiac arrests or appropriate device shocks). Cox univariate analysis identified smoking, New York Heart Association functional class, blood pressure, LV and right ventricular end-diastolic and end-systolic volumes, LV EF, right ventricular EF, and late gadolinium enhancement as predictors of MACE. In multivariate analysis, only LV EF and late gadolinium enhancement were independent predictors of MACE-free survival (hazard ratio: 0.922, 95% CI: 0.878 to 0.967, p = 0.001 and HR: 1.096, 95% CI: 1.004 to 1.197, p = 0.04, respectively). Neither NC/C length nor NC/C mass had significant predictive value for MACE-free survival, either unadjusted or after adjustment for baseline variables. Also, there was no difference in cardioembolic event
- Published
- 2015
43. Traitement des dyslipidémies et risque de cardiopathie ischémique dans le diabète: méta-analyse de 198.930 patients inclus dans 57 études randomisées
- Author
-
UCL - (SLuc) Service d'endocrinologie et de nutrition, UCL - SSS/IREC/CARD - Pôle de recherche cardiovasculaire, UCL - SSS/IREC/EDIN - Pôle d'endocrinologie, diabète et nutrition, Hermans, Michel, Ahn, Sylvie, Rousseau, Michel, UCL - (SLuc) Service d'endocrinologie et de nutrition, UCL - SSS/IREC/CARD - Pôle de recherche cardiovasculaire, UCL - SSS/IREC/EDIN - Pôle d'endocrinologie, diabète et nutrition, Hermans, Michel, Ahn, Sylvie, and Rousseau, Michel
- Abstract
Le diabète est un facteur de risque cardiovasculaire (CV) majeur; son influence sur le taux de survenue d’événements CV au cours d'un essai clinique qui inclut une sous-cohorte de diabétiques n'a pas encore fait l'objet d'une évaluation quantifiée. Ce travail a déterminé dans quelle mesure un diabète à l'inclusion, à titre individuel ou à un niveau de sous-groupe de patients, augmente le risque résiduel CV au cours d'un essai clinique randomisé. Cette méta-analyse a repris les critères principaux d’essais prospectifs- clés, pour lesquels la proportion de diabétiques à l’inclusion était connue, y compris les études ayant spécifiquement rapporté des résultats pour leurs sous-groupes de diabétiques. L’analyse a permis de quantifier formellement la relation linéaire entre la prévalence du diabète et les taux de maladies CV. La composante de risque CV absolu et relatif résiduel associé à la présence à l’inclusion de diabétiques peut ainsi être facilement prédite à partir d’équations linéa, [Treatment of dyslipidemia and cardiovascular risk in diabetes: a meta-analysis of 198.930 patients included in 57 randomized studies] Diabetes is a major cardiovascular (CV) risk factor; its influence on the rate of occurrence of CV events during a clinical trial that includes a sub-cohort of diabetics has not been quantified. This work determined the extent to which diabetes at baseline, individually or at a sub-group level, increases residual CV risk during a randomized clinical trial. This meta-analysis reviewed landmark prospective lipid-lowering trials for which the proportions of diabetes at baseline were known, including studies having specifically reported results for their diabetic subgroups. The analysis allowed to formally quantify the linear relationship between the prevalence of diabetes at baseline and primary CV outcomes rates. The absolute residual CVD risk component associated with the presence of diabetes at inclusion can be easily predicted from these linear equations relating the prevalence of diabetes to various CV outcomes.
- Published
- 2015
44. 1,25-Dihydroxyvitamin D to PTH(1–84) Ratios Strongly Predict Cardiovascular Death in Heart Failure
- Author
-
UCL - SSS/IREC/EDIN - Pôle d'endocrinologie, diabète et nutrition, UCL - SSS/IREC/CARD - Pôle de recherche cardiovasculaire, UCL - (SLuc) Service de biochimie médicale, UCL - (SLuc) Service de pathologie cardiovasculaire, Gruson, Damien, Ferracin, Benjamin, Ahn, Sylvie A., Zierold, Claudia, Blocki, Frank, Hawkins, Douglas M., Bonelli, Fabrizio, Rousseau, Michel, Passino, Claudio, UCL - SSS/IREC/EDIN - Pôle d'endocrinologie, diabète et nutrition, UCL - SSS/IREC/CARD - Pôle de recherche cardiovasculaire, UCL - (SLuc) Service de biochimie médicale, UCL - (SLuc) Service de pathologie cardiovasculaire, Gruson, Damien, Ferracin, Benjamin, Ahn, Sylvie A., Zierold, Claudia, Blocki, Frank, Hawkins, Douglas M., Bonelli, Fabrizio, Rousseau, Michel, and Passino, Claudio
- Abstract
Objectives: Vitamin D deficiency and hyperparathyroidism are common in patients with heart failure (HF). There is a growing body of evidence supporting the role of vitamin D and parathyroid hormone (PTH) in cardiac remodeling and worsening of HF. Lack of reliable automated testing of 1,25-dihydroxyvitamin D (1,25(OH)2D), the biologically active metabolite of vitamin D, has limited its contribution to the prognostic assessment of HF. Here, the association of 1,25(OH)2D and PTH(1–84) levels was evaluated for prediction of cardiovascular death in chronic HF patients. Methods: We conducted a single center prospective cohort including 170 chronic HF patients (females n = 36; males n = 134; NYHA II-IV; mean age: 67 years; etiology: ischemic n = 119, dilated cardiomyopathy n = 51; mean LVEF: 23%). The primary outcome was cardiovascular death. Results: Serum levels of 1,25(OH)2D decreased markedly with increased HF severity. Medians were 33.3 pg/mL for NYHA-II patients, 23.4 pg/mL for NYHA-III, and 14.0 pg/mL for NYHA-IV patients (p<0.001). Most patients had levels of 25(OH)D below 30ng/mL, and stratification by NYHA functional class did not show significant differences (p = 0.249). The 1,25(OH)2D to PTH(1–84) ratio and the (1,25(OH)2D)2 to PTH(1–84) ratio were found to be the most significantly related to HF severity. After a median follow-up of 4.1 years, 106 out of 170 patients reached the primary endpoint. Cox proportional hazard modeling revealed 1,25(OH)2D and the 1,25(OH)2D to PTH(1–84) ratios to be strongly predictive of outcomes. Conclusions: 1,25(OH)2D and its ratios to PTH(1–84) strongly and independently predict cardiovascular mortality in chronic HF.
- Published
- 2015
45. 1,25-Dihydroxyvitamin D to PTH(1–84) Ratios Strongly Predict Cardiovascular Death in Heart Failure
- Author
-
Gruson, Damien, primary, Ferracin, Benjamin, additional, Ahn, Sylvie A., additional, Zierold, Claudia, additional, Blocki, Frank, additional, Hawkins, Douglas M., additional, Bonelli, Fabrizio, additional, and Rousseau, Michel F., additional
- Published
- 2015
- Full Text
- View/download PDF
46. Prognostic Impact of Hypertrabeculation and Noncompaction Phenotype in Dilated Cardiomyopathy
- Author
-
Amzulescu, Mihaela-Silvia, primary, Rousseau, Michel F., additional, Ahn, Sylvie A., additional, Boileau, Laurianne, additional, de Meester de Ravenstein, Christophe, additional, Vancraeynest, David, additional, Pasquet, Agnes, additional, Vanoverschelde, Jean Louis, additional, Pouleur, Anne-Catherine, additional, and Gerber, Bernhard L., additional
- Published
- 2015
- Full Text
- View/download PDF
47. Baseline diabetes as a way to predict CV outcomes in a lipid-modifying trial: a meta-analysis of 330,376 patients from 47 landmark studies
- Author
-
Hermans, Michel P., primary, Bouenizabila, Evariste, additional, Amoussou-guenou, Daniel K., additional, Ahn, Sylvie A., additional, and Rousseau, Michel F., additional
- Published
- 2015
- Full Text
- View/download PDF
48. SOLUBLE RECEPTOR FMS LIKE TYROSINE KINASE 1 TESTING IN HEART FAILURE PATIENTS WITH REDUCED EJECTION FRACTION
- Author
-
Gruson, Damien, primary, Ferracin, Benjamin, additional, Ahn, Sylvie, additional, and Rousseau, Michel, additional
- Published
- 2015
- Full Text
- View/download PDF
49. Galectin-3 testing: Validity of a novel automated assay in heart failure patients with reduced ejection fraction
- Author
-
UCL - SSS/IREC/CARD - Pôle de recherche cardiovasculaire, UCL - SSS/IREC/EDIN - Pôle d'endocrinologie, diabète et nutrition, UCL - (SLuc) Service de pathologie cardiovasculaire, UCL - (SLuc) Service de biochimie médicale, Gruson, Damien, Mancini, Mehdi, Ahn, Sylvie A., Rousseau, Michel, UCL - SSS/IREC/CARD - Pôle de recherche cardiovasculaire, UCL - SSS/IREC/EDIN - Pôle d'endocrinologie, diabète et nutrition, UCL - (SLuc) Service de pathologie cardiovasculaire, UCL - (SLuc) Service de biochimie médicale, Gruson, Damien, Mancini, Mehdi, Ahn, Sylvie A., and Rousseau, Michel
- Abstract
Circulating levels of galectin-3 (Gal-3), a marker of cardiac fibrosis and remodeling, contribute to the risk stratification of patients with heart failure (HF). The aim of our study was to determine the analytical validity and clinical validity of a novel automated Gal-3 assay in HF patients with reduced ejection fraction. We showed an excellent agreement between the VIDAS® Gal-3 automated assay and the ELISA reference method (r = 0.90, p. <. 0.001) and a mean difference of - 1.3. ng/mL was observed on the Bland and Altman plot. Gal-3 levels measured with the VIDAS® assay were significantly related to NYHA functional classes (p. <. 0.001) and mean Gal-3 levels were 13.8. ng/mL in NYHA II patients, 17.7. ng/mL in NYHA III and 19.6. ng/mL in NYHA IV. Furthermore, our results showed that Gal-3 levels measured with the VIDAS® assay were not only predictive of long-term cardiovascular death in patients with systolic HF but have also provided added value to natriuretic peptide testing in multimarker strategies. Therefore, our data are also supporting the clinical validity of the Gal-3 automated assay. © 2013.
- Published
- 2014
50. Novel sexual dimorphisms of sleep apnea syndrome in diabetes
- Author
-
UCL - SSS/IREC/CARD - Pôle de recherche cardiovasculaire, UCL - SSS/IREC/EDIN - Pôle d'endocrinologie, diabète et nutrition, UCL - (SLuc) Service de pathologie cardiovasculaire, UCL - (SLuc) Service d'endocrinologie et de nutrition, Hermans, Michel, Mahadeb, Yovan P., Katchunga, Philippe, Cikomola Cirhuza, Justin, Ahn, Sylvie A., Rousseau, Michel, UCL - SSS/IREC/CARD - Pôle de recherche cardiovasculaire, UCL - SSS/IREC/EDIN - Pôle d'endocrinologie, diabète et nutrition, UCL - (SLuc) Service de pathologie cardiovasculaire, UCL - (SLuc) Service d'endocrinologie et de nutrition, Hermans, Michel, Mahadeb, Yovan P., Katchunga, Philippe, Cikomola Cirhuza, Justin, Ahn, Sylvie A., and Rousseau, Michel
- Abstract
Background: OSAS, a frequently neglected, yet frequent comorbidity in T2DM, is associated with obesity, metabolic syndrome and central fat. OSAS is better documented in males, and this study explored novel gender dimorphisms in T2DM. Methods: Cross-sectional study: 815 T2DM (541 males; 274 females) classified into OSAS[-] and OSAS[+] were assessed for cardiometabolic risk factors, glucose homeostasis, micro/macroangiopathies, CV risk, autoimmune thyroid disease (AITD); and GAD65 antibodies. Results: There was a gender dimorphism in glucose control (worse in females), apolipoprotein B100 (higher in females), with apoB100/apoA1 and log(TG)/HDL-C sexually dimorphic. There was also a marked gender dimorphism in GAD65 positivity, higher (+793%) in OSAS[+] females vs. males. There were clear sexual dimorphisms in macro-/microangioathies, regarding stroke, retinopathy and polyneuropathy. OSAS was not sexually dimorphic regarding age; education; and diabetes duration. There was a significant dimorphism in ethnicity. There were no gender-specific dimorphisms related to OSAS in anthropometrics, nor in hypertension, insulin sensitivity, or hyperbolic product loss rate. Conclusion: We report a series of novel OSAS-related sexual dimorphisms, concerning GAD65 auto-antibodies; polyneuropathy; atherogenic dyslipidemia [all increased in females]; diabetic retinopathy; North-Caucasian ethnicity; metabolic control; and TIA/stroke prevalence [all lower in females]. These findings raise challenging questions regarding the reciprocal pathophysiology between obstructive sleep disorders and cardiometabolic risk in T2DM. © 2013 Diabetes. Published by Elsevier Ltd. All rights reserved.
- Published
- 2014
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.